Navigation Links
Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
Date:11/6/2013

SAN DIEGO, Nov. 6, 2013 /PRNewswire/ -- Polaris Group announced today that the first patient has been dosed in its Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of Relapsed/Refractory Acute Myeloid Leukemia. Polaris Group is conducting clinical trials on ADI-PEG 20 for the treatment of several other indications, including hepatocellular carcinoma. The latter indication is already in a global Phase 3 study.

(Logo: http://photos.prnewswire.com/prnh/20131106/LA12039LOGO)

"Data from our collaborators show that acute myeloid leukemia cells require the amino acid arginine for growth, and that deprivation of arginine by ADI inhibits leukemia cell growth," said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris Group. "Treatment options for patients who have this form of leukemia are limited. We are pleased that the first patient in this trial has been treated with ADI-PEG 20 and we hope that ADI-PEG 20 will be of benefit to patients in this trial."

About ADI-PEG 20
ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group
Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company's lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com


'/>"/>
SOURCE Polaris Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
2. GSI Group Announces Financial Results for the Third Quarter 2013
3. CAO Group Launches New Pilot Diode Laser System
4. Simcere Pharmaceutical Group to Announce Third Quarter 2013 Financial Results on Thursday, November 14, 2013
5. Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety
6. InspireMDs MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
7. Securus Medical Group Raises $6.5M, Appoints New CEO
8. Pediatric Group Offers Consistent Vision Care Across Its Network with Spot Vision Screener
9. Long Island Plastic Surgical Group (LIPSG) Nominated in Four Categories for Best of Long Island 2014 Awards
10. Private Hospital Group in Spain Expands Radiotherapy Capabilities with Countrys First Elekta Versa HD System
11. Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016  While Abbott,s announced purchase ... company,s valve repair and stent business, healthcare research ... Abbott more firmly into patient monitoring.  Kalorama said ... growing device areas, with double-digit growth expected the ... Advanced Remote Patient Monitoring . Abbott ...
(Date:4/28/2016)... 28, 2016  The blood testing market in ... to Kalorama Information and The Freedonia Group in a ... acid testing.  The healthcare research firm said that ... blood collection stations and in improving testing at the ... report, Blood Testing Market in China ...
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the dentists ... dentistry is a fast-growing field as more patients are discovering the many different ways ... about the options currently available to them and which ones might work for their ...
(Date:4/29/2016)... ... ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a leading ... specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , A ... safety device secured by nasal surgeons onto the floor of the nasal passages, at ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market leader ... led by Eastside Partners, with participation from existing investor Martin Ventures. The ... accelerate its technology and product roadmap. , “Jvion is experiencing significant ...
(Date:4/29/2016)... ... ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of 100 on ... place for Tampa’s Best Places to Work. They were ranked in the Big Category, ... for our team,” says RMS Human Resources Manager Irene Miller. “We work hard to ...
(Date:4/29/2016)... Newport Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Dr. Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are ... the Society for Assisted Reproductive Technology (SART). In April, SART published the ...
Breaking Medicine News(10 mins):